Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Metastatic Pancreatic Cancer
NCT00544908Phase 2Terminated
- Sponsor
- City of Hope
- Start
- Sep 2007
- Primary completion
- Oct 2012
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in pancreatic cancer (PC), sponsored by City of Hope. Started Sep 2007; status: terminated.
02
Drugs
dasatinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00544908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00544908.